Abstract 3270
Background
Symptoms of anxiety and depression are common in patients with cancer, and associated with impaired quality of life (QoL). The aim was to evaluate the effect of internet-based stepped care (iCAN-DO) on symptoms of anxiety and depression and QoL in patients with cancer, compared to standard care (SC).
Methods
iCAN-DO was developed in cooperation between professionals and patients with cancer. Consecutive patients (N = 245), with self-reported symptoms of anxiety and/or depression, according to the Hospital Anxiety and Depression Scale, were randomized to iCAN-DO or SC. iCAN-DO comprised interactive support, including psycho-education and self-care strategies (Step 1), and cognitive behavioural therapy (Step 2) for those with persistent symptoms 1, 4 and/or 7 months post randomization. Data was collected before randomization and at 1, 4, 7 and 10 months post randomization.
Results
One-hundred and five of 124 patients (85%) used iCAN-DO to some extent and 49% completed the 10 months assessment. Patients randomized to iCAN-DO reported lower levels of symptoms of depression (mean 7.3 vs 6.2), and a clinically significant decrease of depression from baseline to 10 months (decrease 23% vs 8%), compared to standard care (p < 0.05). In addition, the proportion of patients with clinical depression was smaller in iCAN-DO (15% vs 23%) compared to SC, at 10 months (p < 0.05). There was now difference between iCAN-DO and SC with regard to symptoms of anxiety and QoL.
Conclusions
Internet-based stepped care for patients with cancer who self-report symptoms of anxiety and/or depression is effective to decrease depression, for some patients. Further studies are needed to develop internet-based support to suit different needs, and competence to use information technologies.
Clinical trial identification
NCT01630681.
Editorial acknowledgement
Legal entity responsible for the study
Uppsala University Psychosocial Care Programme.
Funding
Swedish government, Forte Research Council, Swedish Cancer Society, Uppsala County Council.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5128 - IO-Synthesise NSCLC: A pooled analysis of real-world survival outcomes for non-small cell lung cancer patients treated with nivolumab in France and Germany
Presenter: Adrien Dixmier
Session: Poster Display session 1
Resources:
Abstract
2066 - Second-line (2L) real-world treatment (tx) patterns and outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) treated with first line (1L) immuno-oncology (IO) monotherapy (mono tx)
Presenter: Denis Talbot
Session: Poster Display session 1
Resources:
Abstract
5919 - Real-world effectiveness of nivolumab monotherapy after prior systemic therapy in advanced non-small cell lung cancer (NSCLC) in the United States
Presenter: David Stenehjem
Session: Poster Display session 1
Resources:
Abstract
3368 - Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population
Presenter: Nikolaj Frost
Session: Poster Display session 1
Resources:
Abstract
3775 - Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Frank Griesinger
Session: Poster Display session 1
Resources:
Abstract
3926 - Impact of second-line (2L) immune checkpoint inhibitors (ICIs) on the treatment (Tx) of advanced non-small cell lung cancer (NSCLC) in a UK centre: a REAL-Oncology analysis from the I-O Optimise initiative
Presenter: Michael Snee
Session: Poster Display session 1
Resources:
Abstract
5068 - First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort
Presenter: Karim Amrane
Session: Poster Display session 1
Resources:
Abstract
1182 - Interstitial lung disease induced by immune-checkpoint inhibitors correlates with prognosis of advanced non-small-cell lung cancer patients
Presenter: Teppei Sugano
Session: Poster Display session 1
Resources:
Abstract
2297 - Phase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE)
Presenter: Yosuke Kawashima
Session: Poster Display session 1
Resources:
Abstract
2739 - Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
Presenter: Christian Grohe
Session: Poster Display session 1
Resources:
Abstract